Aberrant Mucin5B expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry

Clinical Proteomics

Qing Kay Li¹  Edward Gabrielson²  Frederic Askin²  Xiangchun Wang²  MingHui Ao²  Hui Zhang²  Yan Li³ 

[1] Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USADepartment of Pathology, The Johns Hopkins Bayview Medical Center, Baltimore, USADepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USADepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USADepartment of Pathology, The Johns Hopkins Bayview Medical Center, Baltimore, USADepartment of Pathology, The Johns Hopkins Bayview Medical Center, Baltimore, USADepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USADepartment of Pathology, The Johns Hopkins Bayview Medical Center, Baltimore, USA;Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USADepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USADepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USA;Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USAInstitute of Biophysics, Chanyang, Beijing, P. R. ChinaDepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USADepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USAInstitute of Biophysics, Chanyang, Beijing, P. R. ChinaInstitute of Biophysics, Chanyang, Beijing, P. R. ChinaDepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, USAInstitute of Biophysics, Chanyang, Beijing, P. R. China

关键词: Non-small cell lung cancer;    Lung adenocarcinoma;    Expression of mucin5B;    Quantitative proteomics and iTRAQ labeling;    Immunohistochemistry;   

DOI  :  10.1186/1559-0275-10-15

来源: Humana Press Inc

【 摘 要 】

Abstract

Background

Lung cancer is the number one cause of cancer-related deaths in the United States and worldwide. The complex protein changes and/or signature of protein expression in lung cancer, particularly in non-small cell lung cancer (NSCLC) has not been well defined. Although several studies have investigated the protein profile in lung cancers, the knowledge is far from complete. Among early studies, mucin5B (MUC5B) has been suggested to play an important role in the tumor progression. MUC5B is the major gel-forming mucin in the airway. In this study, we investigated the overall protein profile and MUC5B expression in lung adenocarcinomas, the most common type of NSCLCs.

Methods

Lung adenocarcinoma tissue in formalin-fixed paraffin-embedded (FFPE) blocks was collected and microdissected. Peptides from 8 tumors and 8 tumor-matched normal lung tissue were extracted and labeled with 8-channel iTRAQ reagents. The labeled peptides were identified and quantified by LC-MS/MS using an LTQ Orbitrap Velos mass spectrometer. MUC5B expression identified by iTRAQ labeling was further validated using immunohistochemistry (IHC) on tumor tissue microarray (TMA).

Results

A total of 1288 peptides from 210 proteins were identified and quantified in tumor tissues. Twenty-two proteins showed a greater than 1.5-fold differences between tumor and tumor-matched normal lung tissues. Fifteen proteins, including MUC5B, showed significant changes in tumor tissues. The aberrant expression of MUC5B was further identified in 71.1% of lung adenocarcinomas in the TMA.

Discussions

A subset of tumor-associated proteins was differentially expressed in lung adenocarcinomas. The differential expression of MUC5B in lung adenocarcinomas suggests its role as a potential biomarker in the detection of adenocarcinomas.

【 授权许可】

Unknown